Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twinlab

This article was originally published in The Tan Sheet

Executive Summary

Ephedra-containing products comprised about 20% of third quarter sales, Chairman & CEO Ross Blechman reports during an analysts call Nov. 11. Although he says recent ephedra studies in prominent medical journals are "old news," Blechman notes the firm is posting strong labeling warnings on products and is preparing for contingencies related to changes in federal policy toward the controversial herbal. Twinlab recorded a net loss of $11.1 mil. for the quarter, compared to income of $2.8 mil. in the 1999 period. Additional earnings details come after the company had to file an extension for its 10-Q due to inventory problems (1"The Tan Sheet" Nov. 20, p. 5)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS091946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel